| Year |
Citation |
Score |
| 2023 |
Zhang Z, Markmann C, Yu M, Agarwal D, Rostami S, Wang W, Liu C, Zhao H, Ochoa T, Parvathaneni K, Xu X, Li E, Gonzalez V, Khadka R, Hoffmann J, ... ... Milone MC, et al. Immunotherapy targeting B cells and long-lived plasma cells effectively eliminates pre-existing donor-specific allo-antibodies. Cell Reports. Medicine. 4: 101336. PMID 38118406 DOI: 10.1016/j.xcrm.2023.101336 |
0.388 |
|
| 2023 |
Glisovic-Aplenc T, Diorio C, Chukinas JA, Veliz K, Shestova O, Shen F, Nunez-Cruz S, Vincent TL, Miao F, Milone MC, June CH, Teachey DT, Tasian SK, Aplenc R, Gill SI. CD38 as a pan-hematologic target for chimeric antigen receptor T cells. Blood Advances. PMID 37171449 DOI: 10.1182/bloodadvances.2022007059 |
0.492 |
|
| 2023 |
Oh S, Mao X, Manfredo-Vieira S, Lee J, Patel D, Choi EJ, Alvarado A, Cottman-Thomas E, Maseda D, Tsao PY, Ellebrecht CT, Khella SL, Richman DP, O'Connor KC, Herzberg U, ... ... Milone MC, et al. Precision targeting of autoantigen-specific B cells in muscle-specific tyrosine kinase myasthenia gravis with chimeric autoantibody receptor T cells. Nature Biotechnology. PMID 36658341 DOI: 10.1038/s41587-022-01637-z |
0.386 |
|
| 2022 |
Song EZ, Wang X, Philipson BI, Zhang Q, Thokala R, Zhang L, Assenmacher CA, Binder ZA, Ming GL, O'Rourke DM, Song H, Milone MC. The IAP antagonist birinapant enhances chimeric antigen receptor T cell therapy for glioblastoma by overcoming antigen heterogeneity. Molecular Therapy Oncolytics. 27: 288-304. PMID 36458202 DOI: 10.1016/j.omto.2022.11.004 |
0.494 |
|
| 2022 |
Garfall AL, Cohen AD, Susanibar-Adaniya SP, Hwang WT, Vogl DT, Waxman AJ, Lacey SF, Gonzalez VE, Fraietta JA, Gupta M, Kulikovskaya I, Tian L, Chen F, Koterba N, Bartoszek RL, ... ... Milone MC, et al. Anti-BCMA/CD19 CAR T cells with early immunomodulatory maintenance for multiple myeloma responding to initial or later-line therapy. Blood Cancer Discovery. PMID 36413381 DOI: 10.1158/2643-3230.BCD-22-0074 |
0.315 |
|
| 2022 |
Zhang Q, Yang J, Manoharan ENEA, Yu AB, Milone MC. CRISPR/Cas9-mediated Gene Knockout Followed by Negative Selection Leads to a Complete TCR Depletion in CAR19 T Cells. Bio-Protocol. 12. PMID 36389275 DOI: 10.21769/BioProtoc.4485 |
0.397 |
|
| 2022 |
Ellis GI, Deng MZ, Winn DW, Coker KE, Shukla D, Bhoj V, Milone MC, Duran-Struuck R, Riley JL. Generation of non-human primate CAR Tregs using artificial antigen-presenting cells, simian tropic lentiviral vectors, and antigen-specific restimulation. Star Protocols. 3: 101784. PMID 36386869 DOI: 10.1016/j.xpro.2022.101784 |
0.405 |
|
| 2022 |
Dhodapkar KM, Cohen AD, Kaushal A, Garfall AL, Manalo RJ, Carr AR, McCachren SS, Stadtmauer EA, Lacey SF, Melenhorst JJ, June CH, Milone MC, Dhodapkar MV. Changes in Bone Marrow Tumor and Immune Cells Correlate with Durability of Remissions Following BCMA CAR T Therapy in Myeloma. Blood Cancer Discovery. OF1-OF12. PMID 36026513 DOI: 10.1158/2643-3230.BCD-22-0018 |
0.456 |
|
| 2022 |
Zhang H, Yu P, Tomar VS, Chen X, Atherton MJ, Lu Z, Zhang HG, Li S, Ortiz A, Gui J, Leu NA, Yan F, Blanco A, Meyer-Ficca ML, Meyer RG, ... ... Milone MC, et al. Targeting PARP11 to avert immunosuppression and improve CAR T therapy in solid tumors. Nature Cancer. PMID 35637402 DOI: 10.1038/s43018-022-00383-0 |
0.414 |
|
| 2022 |
Ellis GI, Coker KE, Winn DW, Deng MZ, Shukla D, Bhoj V, Milone MC, Wang W, Liu C, Naji A, Duran-Struuck R, Riley JL. Trafficking and persistence of alloantigen-specific chimeric antigen receptor regulatory T cells in Cynomolgus macaque. Cell Reports. Medicine. 100614. PMID 35551746 DOI: 10.1016/j.xcrm.2022.100614 |
0.319 |
|
| 2022 |
Ghassemi S, Durgin JS, Nunez-Cruz S, Patel J, Leferovich J, Pinzone M, Shen F, Cummins KD, Plesa G, Cantu VA, Reddy S, Bushman FD, Gill SI, O'Doherty U, O'Connor RS, ... Milone MC, et al. Rapid manufacturing of non-activated potent CAR T cells. Nature Biomedical Engineering. 6: 118-128. PMID 35190680 DOI: 10.1038/s41551-021-00842-6 |
0.401 |
|
| 2022 |
Milone MC, Xu J, Chen SJ, Collins MA, Zhou J, Powell DJ, Melenhorst JJ. Author Correction: Engineering-enhanced CAR T cells for improved cancer therapy. Nature Cancer. 2: 1113. PMID 35121886 DOI: 10.1038/s43018-021-00277-7 |
0.342 |
|
| 2021 |
Durgin JS, Thokala R, Johnson L, Song E, Leferovich J, Bhoj V, Ghassemi S, Milone M, Binder Z, O'Rourke DM, O'Connor RS. Enhancing CAR T Function with the Engineered Secretion of C. Perfringens Neuraminidase. Molecular Therapy : the Journal of the American Society of Gene Therapy. PMID 34813961 DOI: 10.1016/j.ymthe.2021.11.014 |
0.44 |
|
| 2021 |
Garcia-Canaveras JC, Heo D, Trefely S, Leferovich J, Xu C, Philipson BI, Ghassemi S, Milone MC, Moon EK, Snyder NW, June CH, Rabinowitz JD, O'Connor RS. CAR T-Cells Depend on the Coupling of NADH Oxidation with ATP Production. Cells. 10. PMID 34571983 DOI: 10.3390/cells10092334 |
0.381 |
|
| 2021 |
Thokala R, Binder ZA, Yin Y, Zhang L, Zhang JV, Zhang DY, Milone MC, Ming GL, Song H, O'Rourke DM. High-Affinity Chimeric Antigen Receptor With Cross-Reactive scFv to Clinically Relevant EGFR Oncogenic Isoforms. Frontiers in Oncology. 11: 664236. PMID 34568006 DOI: 10.3389/fonc.2021.664236 |
0.42 |
|
| 2021 |
Manjunath SH, Cohen AD, Lacey SF, Davis MM, Garfall AL, Melenhorst JJ, Maxwell R, Arscott WT, Maity A, Jones JA, Plastaras JP, Stadtmauer EA, Levine BL, June CH, Milone MC, et al. The Safety of Bridging Radiation with Anti-BCMA CAR T-Cell Therapy for Multiple Myeloma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 34526365 DOI: 10.1158/1078-0432.CCR-21-0308 |
0.363 |
|
| 2021 |
Milone MC, Xu J, Chen SJ, Collins MA, Zhou J, Powell DJ, Melenhorst JJ. Engineering enhanced CAR T-cells for improved cancer therapy. Nature Cancer. 2: 780-793. PMID 34485921 DOI: 10.1038/s43018-021-00241-5 |
0.451 |
|
| 2021 |
Bernabei L, Tian L, Garfall AL, Melenhorst JJ, Lacey SF, Stadtmauer EA, Vogl DT, Gonzalez VE, Plesa G, Young RM, Waxman A, Levine BL, June CH, Milone MC, Cohen AD. B-cell maturation antigen chimeric antigen receptor T-cell re-expansion in a patient with myeloma following salvage programmed cell death protein 1 inhibitor-based combination therapy. British Journal of Haematology. PMID 33713436 DOI: 10.1111/bjh.17397 |
0.391 |
|
| 2021 |
Bhoj VG, Li L, Parvathaneni K, Zhang Z, Kacir S, Arhontoulis D, Zhou K, McGettigan-Croce B, Nunez-Cruz S, Gulendran G, Boesteanu AC, Johnson L, Feldman MD, Radaelli E, Mansfield K, ... ... Milone MC, et al. Adoptive T cell immunotherapy for medullary thyroid carcinoma targeting GDNF family receptor alpha 4. Molecular Therapy Oncolytics. 20: 387-398. PMID 33614919 DOI: 10.1016/j.omto.2021.01.012 |
0.507 |
|
| 2021 |
Wilson W, Miao F, Garfall AL, Bu D, Orlando EJ, Brogdon JL, Pruteanu-Malinici I, Cohen AD, Milone MC. Perfecting CAR Engraftment to a Tee (Cell) through Characterization of Single Cell Transcriptome Product and Understanding Neurotoxicity Blood. 138: 1707-1707. DOI: 10.1182/blood-2021-151785 |
0.405 |
|
| 2021 |
Milone MC, Xu J, Chen S, Collins MA, Zhou J, Powell DJ, Melenhorst JJ. Author Correction: Engineering-enhanced CAR T cells for improved cancer therapy Nature Cancer. 2: 1113-1113. DOI: 10.1038/s43018-021-00277-7 |
0.342 |
|
| 2020 |
Song EZ, Milone MC. Pharmacology of Chimeric Antigen Receptor-Modified T Cells. Annual Review of Pharmacology and Toxicology. PMID 33035447 DOI: 10.1146/annurev-pharmtox-031720-102211 |
0.469 |
|
| 2020 |
Huarte E, O'Conner RS, Peel MT, Nunez-Cruz S, Leferovich J, Juvekar A, Yang YO, Truong L, Huang T, Naim A, Milone MC, Smith PA. Itacitinib (INCB039110), a JAK1 inhibitor, Reduces Cytokines Associated with Cytokine Release Syndrome Induced by CAR T-Cell Therapy. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 32998963 DOI: 10.1158/1078-0432.CCR-20-1739 |
0.38 |
|
| 2020 |
Ghassemi S, Martinez-Becerra FJ, Master AM, Richman SA, Heo D, Leferovich J, Tu Y, García-Cañaveras JC, Ayari A, Lu Y, Wang A, Rabinowitz JD, Milone MC, June CH, O'Connor RS. Enhancing Chimeric Antigen Receptor T Cell Anti-tumor Function through Advanced Media Design. Molecular Therapy. Methods & Clinical Development. 18: 595-606. PMID 32775494 DOI: 10.1016/J.Omtm.2020.07.008 |
0.426 |
|
| 2020 |
Richman SA, Wang LC, Khire UR, Albelda SM, Milone MC. Ligand-Induced Degradation of a CAR Permits Reversible Remote Control of CAR T Cell Activity In Vitro and In Vivo. Molecular Therapy : the Journal of the American Society of Gene Therapy. PMID 32559430 DOI: 10.1016/j.ymthe.2020.06.004 |
0.386 |
|
| 2020 |
Philipson BI, O'Connor RS, May MJ, June CH, Albelda SM, Milone MC. 4-1BB costimulation promotes CAR T cell survival through noncanonical NF-κB signaling. Science Signaling. 13. PMID 32234960 DOI: 10.1126/Scisignal.Aay8248 |
0.413 |
|
| 2020 |
O'Connor RS, Milone MC. Testing the Specificity of Compounds Designed to Inhibit CPT1A in T Cells. Methods in Molecular Biology (Clifton, N.J.). 2097: 83-90. PMID 31776920 DOI: 10.1007/978-1-0716-0203-4_5 |
0.387 |
|
| 2020 |
Zhang Q, Hresko M, Hollander MJ, Picton L, Su L, Nunez-Cruz S, Sockolosky JT, Garcia K, Milone MC. Human Orthogonal IL-2/IL-2Rβ As a Tunable Approach to Enhance CD19-Speific CAR-T Cell Antitumor Activity Blood. 136: 48-48. DOI: 10.1182/BLOOD-2020-140463 |
0.366 |
|
| 2020 |
Thokala R, Binder Z, Yin Y, Milone M, O’Rourke DM. IMMU-36. HIGH AFFINITY CHIMERIC ANTIGEN RECEPTOR WITH CROSS-REACTIVITY TO CLINICALLY-RELEVANT EGFR MUTATED PROTEINS Neuro-Oncology. 22: ii112-ii112. DOI: 10.1093/neuonc/noaa215.466 |
0.303 |
|
| 2020 |
Ghassemi S, Martinez-Becerra F, Master A, Richman S, Heo D, Leferovich J, Tu Y, Garcia-Canaveras J, Ayari A, Lu Y, Wang A, Rabinowitz J, Milone M, O'Connor R. Novel media formulations to enhance Chimeric Antigen Receptor (CAR) T-cell potency and anti-tumor cell function for adoptive immunotherapy Cytotherapy. 22: S133. DOI: 10.1016/J.Jcyt.2020.03.260 |
0.411 |
|
| 2020 |
Ghassemi S, O'Connor R, Nunez-Cruz S, Leferovich J, Patel J, Milone M. Chimeric Antigen Receptor (CAR) T cells on demand: developing potent CAR T cells in less than 24 hr for adoptive immunotherapy Cytotherapy. 22: S34-S35. DOI: 10.1016/J.Jcyt.2020.03.025 |
0.457 |
|
| 2019 |
Ghassemi S, Milone MC. Manufacturing Chimeric Antigen Receptor (CAR) T Cells for Adoptive Immunotherapy. Journal of Visualized Experiments : Jove. PMID 31904011 DOI: 10.3791/59949 |
0.452 |
|
| 2019 |
Sellmyer MA, Richman SA, Lohith K, Hou C, Weng CC, Mach RH, O'Connor RS, Milone MC, Farwell MD. Imaging CAR T Cell Trafficking with eDFHR as a PET Reporter Gene. Molecular Therapy : the Journal of the American Society of Gene Therapy. PMID 31668558 DOI: 10.1016/J.Ymthe.2019.10.007 |
0.462 |
|
| 2019 |
Garfall AL, Dancy EK, Cohen AD, Hwang WT, Fraietta JA, Davis MM, Levine BL, Siegel DL, Stadtmauer EA, Vogl DT, Waxman A, Rapoport AP, Milone MC, June CH, Melenhorst JJ. T-cell phenotypes associated with effective CAR T-cell therapy in postinduction vs relapsed multiple myeloma. Blood Advances. 3: 2812-2815. PMID 31575532 DOI: 10.1182/Bloodadvances.2019000600 |
0.347 |
|
| 2019 |
Cohen AD, Garfall AL, Stadtmauer EA, Melenhorst JJ, Lacey SF, Lancaster E, Vogl DT, Weiss BM, Dengel K, Nelson A, Plesa G, Chen F, Davis MM, Hwang WT, Young RM, ... ... Milone MC, et al. B cell maturation antigen-specific CAR T cells are clinically active in multiple myeloma. The Journal of Clinical Investigation. 130. PMID 30896447 DOI: 10.1172/Jci126397 |
0.473 |
|
| 2019 |
Garfall AL, Stadtmauer EA, Hwang WT, Lacey SF, Melenhorst JJ, Krevvata M, Carroll MP, Matsui WH, Wang Q, Dhodapkar MV, Dhodapkar K, Das R, Vogl DT, Weiss BM, Cohen AD, ... ... Milone MC, et al. Anti-CD19 CAR T cells with high-dose melphalan and autologous stem cell transplantation for refractory multiple myeloma. Jci Insight. 4. PMID 30830874 DOI: 10.1172/jci.insight.127684 |
0.313 |
|
| 2019 |
Feins S, Kong W, Williams EF, Milone MC, Fraietta JA. An Introduction to Chimeric Antigen Receptor (CAR) T cell Immunotherapy for Human Cancer. American Journal of Hematology. PMID 30680780 DOI: 10.1002/Ajh.25418 |
0.5 |
|
| 2019 |
Ghassemi S, O'Connor RS, Nunez-cruz S, Patel J, Leferovich J, Milone MC. Simple, 1-Day Manufacturing of Quiescent Chimeric Antigen Receptor T Cells for Adoptive Immunotherapy Blood. 134: 4436-4436. DOI: 10.1182/Blood-2019-131147 |
0.454 |
|
| 2019 |
Huarte E, O'Connor RS, Parker M, Huang T, Milone MC, Smith P. Prophylactic Itacitinib (INCB039110) for the Prevention of Cytokine Release Syndrome Induced By Chimeric Antigen Receptor T-Cells (CAR-T-cells) Therapy Blood. 134: 1934-1934. DOI: 10.1182/Blood-2019-128288 |
0.392 |
|
| 2019 |
Wang M, Pruteanu I, Cohen AD, Garfall AL, Tian L, Lacey SF, Fraietta JA, Brogdon J, Davis M, Gonzalez VE, Levine BL, Siegel DL, Milone MC, Stadtmauer EA, June CH, et al. Response to Anti-Bcma CAR T Cell Therapy Correlates with T Cell Exhaustion and Activation Status in T Cells at Baseline in Myeloma Blood. 134: 1909-1909. DOI: 10.1182/Blood-2019-122396 |
0.402 |
|
| 2018 |
Thibodeaux SR, Milone MC. Immunotherapy Using Chimeric Antigen Receptor-Engineered T Cells: A Novel Cellular Therapy with Important Implications for the Clinical Laboratory. Clinical Chemistry. PMID 30593467 DOI: 10.1373/clinchem.2016.258988 |
0.4 |
|
| 2018 |
Ghassemi S, Nunez-Cruz S, O'Connor RS, Fraietta JA, Patel PR, Scholler J, Barrett DM, Lundh SM, Davis MM, Bedoya F, Leferovich J, Lacey SF, Levine BL, Grupp SA, June CH, ... ... Milone MC, et al. Reducing Ex Vivo Culture Improves the Anti-leukemic Activity of Chimeric Antigen Receptor (CAR)-T Cells. Cancer Immunology Research. PMID 30030295 DOI: 10.1158/2326-6066.Cir-17-0405 |
0.449 |
|
| 2018 |
Bu DX, Singh R, Choi EE, Ruella M, Nunez-Cruz S, Mansfield KG, Bennett P, Barton N, Wu Q, Zhang J, Wang Y, Wei L, Cogan S, Ezell T, Joshi S, ... ... Milone MC, et al. Pre-clinical validation of B cell maturation antigen (BCMA) as a target for T cell immunotherapy of multiple myeloma. Oncotarget. 9: 25764-25780. PMID 29899820 DOI: 10.18632/oncotarget.25359 |
0.403 |
|
| 2018 |
Garfall AL, Stadtmauer EA, Hwang WT, Lacey SF, Melenhorst JJ, Krevvata M, Carroll MP, Matsui WH, Wang Q, Dhodapkar MV, Dhodapkar K, Das R, Vogl DT, Weiss BM, Cohen AD, ... ... Milone MC, et al. Anti-CD19 CAR T cells with high-dose melphalan and autologous stem cell transplantation for refractory multiple myeloma. Jci Insight. 3. PMID 29669947 DOI: 10.1172/Jci.Insight.120505 |
0.415 |
|
| 2018 |
Milone MC, O'Doherty U. Clinical use of lentiviral vectors. Leukemia. PMID 29654266 DOI: 10.1038/s41375-018-0106-0 |
0.323 |
|
| 2018 |
Richman SA, Milone MC. Neurotoxicity Associated with a High-Affinity GD2 CAR-Response. Cancer Immunology Research. 6: 496-497. PMID 29610424 DOI: 10.1158/2326-6066.Cir-18-0090 |
0.33 |
|
| 2018 |
June CH, O'Connor RS, Kawalekar OU, Ghassemi S, Milone MC. CAR T cell immunotherapy for human cancer. Science (New York, N.Y.). 359: 1361-1365. PMID 29567707 DOI: 10.1126/Science.Aar6711 |
0.416 |
|
| 2018 |
Milone MC, Bhoj VG. The Pharmacology of T Cell Therapies. Molecular Therapy. Methods & Clinical Development. 8: 210-221. PMID 29552577 DOI: 10.1016/j.omtm.2018.01.010 |
0.399 |
|
| 2018 |
Bhoj V, Li L, Samelson-Jones BJ, Doshi BS, Ellebrecht C, Payne A, Arruda VR, Milone MC. Optimized FVIII-Domain-Based Chimeric Antigen Receptors to Specifically Target FVIII Inhibitor-Producing B Cells in Hemophilia a Blood. 132: 2196-2196. DOI: 10.1182/BLOOD-2018-99-120031 |
0.338 |
|
| 2018 |
Cohen AD, Melenhorst JJ, Garfall AL, Lacey SF, Davis M, Vogl DT, Tian L, Gonzalez V, Pruteanu I, Nelson AM, Plesa G, Waxman A, Young RM, Levine BL, June CH, ... ... Milone MC, et al. Predictors of T Cell Expansion and Clinical Responses Following B-Cell Maturation Antigen-Specific Chimeric Antigen Receptor T Cell Therapy (CART-BCMA) for Relapsed/Refractory Multiple Myeloma (MM) Blood. 132: 1974-1974. DOI: 10.1182/Blood-2018-99-119665 |
0.34 |
|
| 2018 |
Milone MC, OConnor R, May M, Albelda S, Philipson B. 4-1BB-Costimulated CAR-Mediated Non-Canonical NF-Kb Signaling Enhances CAR T Cell Survival and Suppresses Bim Expression Blood. 132: 3713-3713. DOI: 10.1182/blood-2018-99-119522 |
0.429 |
|
| 2018 |
Bernabei L, Garfall AL, Melenhorst JJ, Lacey SF, Stadtmauer EA, Vogl DT, Gonzalez V, Plesa G, Young RM, Waxman A, Levine BL, June CH, Milone MC, Cohen AD. PD-1 Inhibitor Combinations As Salvage Therapy for Relapsed/Refractory Multiple Myeloma (MM) Patients Progressing after Bcma-Directed CAR T Cells Blood. 132: 1973-1973. DOI: 10.1182/Blood-2018-99-119514 |
0.34 |
|
| 2018 |
Dancy E, Garfall AL, Cohen AD, Fraietta JA, Davis M, Levine BL, Siegel DL, Stadtmauer EA, Vogl DT, Waxman A, Rapoport AP, Milone MC, June CH, Melenhorst JJ. Clinical Predictors of T Cell Fitness for CAR T Cell Manufacturing and Efficacy in Multiple Myeloma Blood. 132: 1886-1886. DOI: 10.1182/Blood-2018-99-115319 |
0.355 |
|
| 2018 |
Lee J, Ellebrecht C, Mao X, Nace A, Choi E, Milone M, Payne A. 461 Preclinical development of desmoglein chimeric autoantibody receptor (CAAR) T cells for pemphigus therapy Journal of Investigative Dermatology. 138: S78. DOI: 10.1016/J.JID.2018.03.468 |
0.335 |
|
| 2017 |
Richman SA, Nunez-Cruz S, Moghimi B, Li LZ, Gershenson ZT, Mourelatos Z, Barrett DM, Grupp SA, Milone MC. High-Affinity GD2-Specific CAR T Cells Induce Fatal Encephalitis in a Preclinical Neuroblastoma Model. Cancer Immunology Research. PMID 29180536 DOI: 10.1158/2326-6066.Cir-17-0211 |
0.501 |
|
| 2017 |
Kawalekar O, June CH, Milone MC. Studying Immunoreceptor Signaling in Human T Cells Using Electroporation of In Vitro Transcribed mRNA. Methods in Molecular Biology (Clifton, N.J.). 1584: 443-450. PMID 28255718 DOI: 10.1007/978-1-4939-6881-7_27 |
0.402 |
|
| 2017 |
Lambert L, Goebrecht GK, De Leo SE, O'Connor RS, Nunez-Cruz S, Li TD, Yuan J, Milone MC, Kam LC. Improving T Cell Expansion with a Soft Touch. Nano Letters. PMID 28122453 DOI: 10.1021/Acs.Nanolett.6B04071 |
0.417 |
|
| 2017 |
Ellebrecht C, Mao X, Melenhorst J, Lacey S, Zhao Y, Milone M, Payne A. 035 Temporally controlled B cell depletion with universal chimeric antigen receptor (CAR) T cells for pemphigus vulgaris (PV) therapy Journal of Investigative Dermatology. 137: S6. DOI: 10.1016/J.JID.2017.02.048 |
0.383 |
|
| 2016 |
Ellebrecht CT, Bhoj VG, Nace A, Choi EJ, Mao X, Cho MJ, Di Zenzo G, Lanzavecchia A, Seykora JT, Cotsarelis G, Milone MC, Payne AS. Reengineering chimeric antigen receptor T cells for targeted therapy of autoimmune disease. Science (New York, N.Y.). PMID 27365313 DOI: 10.1126/Science.Aaf6756 |
0.451 |
|
| 2016 |
Bhoj VG, Arhontoulis D, Wertheim G, Capobianchi J, Callahan CA, Ellebrecht CT, Obstfeld AE, Lacey SF, Melenhorst JJ, Nazimuddin F, Hwang WT, Maude SL, Wasik MA, Bagg A, Schuster S, ... ... Milone MC, et al. Persistence of long-lived plasma cells and humoral immunity in individuals responding to CD19-directed CAR T cell therapy. Blood. PMID 27166358 DOI: 10.1182/Blood-2016-01-694356 |
0.352 |
|
| 2016 |
Kawalekar OU, O'Connor RS, Fraietta JA, Guo L, McGettigan SE, Posey AD, Patel PR, Guedan S, Scholler J, Keith B, Snyder N, Blair I, Milone MC, June CH. Distinct Signaling of Coreceptors Regulates Specific Metabolism Pathways and Impacts Memory Development in CAR T Cells. Immunity. 44: 380-390. PMID 26885860 DOI: 10.1016/J.Immuni.2016.01.021 |
0.43 |
|
| 2016 |
Ruella M, Kenderian SS, Shestova O, Fraietta JA, Qayyum S, Zhang Q, Maus MV, Liu X, Nunez-Cruz S, Klichinsky M, Kawalekar OU, Lacey SF, Milone M, Mato AR, Schuster SJ, et al. The Addition of the BTK inhibitor Ibrutinib to Anti-CD19 Chimeric Antigen Receptor T Cells (CART19) Improves Responses against Mantle Cell Lymphoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 26819453 DOI: 10.1158/1078-0432.Ccr-15-1527 |
0.41 |
|
| 2016 |
Schuster SJ, Svoboda J, Nasta S, Chong EA, Porter DL, Landsburg DJ, Mato AR, Bhoj VG, Milone M, Lacey SF, Strelec LE, Zhou AY, Melenhorst JJ, Chew A, Hasskarl J, et al. Recovery of humoral immunity in patients with durable complete responses following chimeric antigen receptor modified t cells directed against CD19 (CTL019). Journal of Clinical Oncology. 34: 7564-7564. DOI: 10.1200/Jco.2016.34.15_Suppl.7564 |
0.3 |
|
| 2016 |
Ghassemi S, Prachi P, Scholler J, Nunez-Cruz S, Barrett DM, Bedoya F, Fraietta JA, Lacey SF, Levine BL, Grupp SA, June CH, Milone MC, Melenhorst JJ. Minimally Ex Vivo Manipulated Gene-Modified T Cells Display Enhanced Tumor Control Blood. 128: 4549-4549. DOI: 10.1182/Blood.V128.22.4549.4549 |
0.412 |
|
| 2016 |
Bhoj VG, Nunez-Cruz S, Zhou K, Arhontoulis D, Feldman M, Mansfield K, Peng H, Rader C, Siegel DL, Milone MC. Abstract 2295: GDNF family receptor alpha 4 (GFRa4)-targeted adoptive T-cell immunotherapy for medullary thyroid carcinoma Cancer Research. 76: 2295-2295. DOI: 10.1158/1538-7445.Am2016-2295 |
0.487 |
|
| 2016 |
Ghassemi S, Bedoya F, Nunez-Cruz S, June C, Melenhorst J, Milone M. 203. Shortened T Cell Culture with IL-7 and IL-15 Provides the Most Potent Chimeric Antigen Receptor (CAR)-Modified T Cells for Adoptive Immunotherapy Molecular Therapy. 24: S79. DOI: 10.1016/S1525-0016(16)33012-X |
0.361 |
|
| 2015 |
Porter DL, Hwang WT, Frey NV, Lacey SF, Shaw PA, Loren AW, Bagg A, Marcucci KT, Shen A, Gonzalez V, Ambrose D, Grupp SA, Chew A, Zheng Z, Milone MC, et al. Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia. Science Translational Medicine. 7: 303ra139. PMID 26333935 DOI: 10.1126/Scitranslmed.Aac5415 |
0.368 |
|
| 2015 |
Wang E, Wang LC, Tsai CY, Bhoj V, Gershenson Z, Moon E, Newick K, Sun J, Lo A, Baradet T, Feldman MD, Barrett D, Puré E, Albelda S, Milone MC. Generation of Potent T-cell Immunotherapy for Cancer Using DAP12-Based, Multichain, Chimeric Immunoreceptors. Cancer Immunology Research. 3: 815-26. PMID 25941351 DOI: 10.1158/2326-6066.Cir-15-0054 |
0.473 |
|
| 2015 |
Xiang Y, Stine ZE, Xia J, Lu Y, O'Connor RS, Altman BJ, Hsieh AL, Gouw AM, Thomas AG, Gao P, Sun L, Song L, Yan B, Slusher BS, Zhuo J, ... ... Milone MC, et al. Targeted inhibition of tumor-specific glutaminase diminishes cell-autonomous tumorigenesis. The Journal of Clinical Investigation. 125: 2293-306. PMID 25915584 DOI: 10.1172/Jci75836 |
0.365 |
|
| 2015 |
Frigault MJ, Lee J, Basil MC, Carpenito C, Motohashi S, Scholler J, Kawalekar OU, Guedan S, McGettigan SE, Posey AD, Ang S, Cooper LJ, Platt JM, Johnson FB, Paulos CM, ... ... Milone MC, et al. Identification of chimeric antigen receptors that mediate constitutive or inducible proliferation of T cells. Cancer Immunology Research. 3: 356-67. PMID 25600436 DOI: 10.1158/2326-6066.Cir-14-0186 |
0.447 |
|
| 2015 |
Ruella M, Kenderian SS, Shestova O, Fraietta JA, Qayyum S, Zhang Q, Maus MV, Liu X, Nunez-Cruz S, Klichinsky M, Kawalekar OU, Milone MC, Lacey SF, Mato A, Schuster SJ, et al. The Addition of the BTK Inhibitor Ibrutinib to Anti-CD19 Chimeric Antigen Receptor T Cells (CART19) Improves Engraftment and Antitumor Responses Against Mantle Cell Lymphoma Blood. 126: 704-704. DOI: 10.1182/Blood.V126.23.704.704 |
0.304 |
|
| 2015 |
Kawalekar OU, O'Connor RS, Fraietta J, Guedan S, Scholler J, Milone MC, June CH. 516. Chimeric Antigen Receptors With Distinct Signaling Domains Can Reprogram T Cells Molecular Therapy. 23: S206-S207. DOI: 10.1016/S1525-0016(16)34125-9 |
0.403 |
|
| 2015 |
Wang E, Wang L, Tsai C, Bhoj V, Albelda S, Moon E, Milone M. 21. Non-CD3-Based Chimeric Antigen Receptor (CARs) with Enhanced Anti-Tumor Activity in Solid Tumors Molecular Therapy. 23: S10. DOI: 10.1016/S1525-0016(16)33625-5 |
0.3 |
|
| 2014 |
Moon EK, Wang LC, Dolfi DV, Wilson CB, Ranganathan R, Sun J, Kapoor V, Scholler J, Puré E, Milone MC, June CH, Riley JL, Wherry EJ, Albelda SM. Multifactorial T-cell hypofunction that is reversible can limit the efficacy of chimeric antigen receptor-transduced human T cells in solid tumors. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 20: 4262-73. PMID 24919573 DOI: 10.1158/1078-0432.Ccr-13-2627 |
0.449 |
|
| 2014 |
Kawalekar OU, O'Connor R, Guedan S, Fraietta J, Posey AD, Scholler J, Milone MC, June CH. Signaling Domain of Chimeric Antigen Receptors Can Reprogram T Cells Blood. 124: 551-551. DOI: 10.1182/Blood.V124.21.551.551 |
0.46 |
|
| 2014 |
Bhoj V, Milone MC, June CH, Porter D, Grupp SA, Melenhorst JJ, Lacey SF, Callahan C, Capobianchi J, Wertheim G, Mahnke Y. Humoral Immunity and Plasma Cell Changes in Patients Responding to CD19-Specific Chimeric Antigen Receptor (CAR)-Modified T-Cell Adoptive Immunotherapy Blood. 124: 1110-1110. DOI: 10.1182/Blood.V124.21.1110.1110 |
0.341 |
|
| 2013 |
Grupp SA, Kalos M, Barrett D, Aplenc R, Porter DL, Rheingold SR, Teachey DT, Chew A, Hauck B, Wright JF, Milone MC, Levine BL, June CH. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. The New England Journal of Medicine. 368: 1509-18. PMID 23527958 DOI: 10.1056/Nejmoa1215134 |
0.468 |
|
| 2013 |
Kunii N, Zhao Y, Jiang S, Liu X, Scholler J, Balagopalan L, Samelson LE, Milone MC, June CH. Enhanced function of redirected human T cells expressing linker for activation of T cells that is resistant to ubiquitylation. Human Gene Therapy. 24: 27-37. PMID 22998346 DOI: 10.1089/Hum.2012.130 |
0.43 |
|
| 2013 |
Milone MC, Kam LC. Investigative and clinical applications of synthetic immune synapses. Wiley Interdisciplinary Reviews. Nanomedicine and Nanobiotechnology. 5: 75-85. PMID 22927243 DOI: 10.1002/wnan.1195 |
0.333 |
|
| 2013 |
Grupp SA, Kalos M, Barrett DM, Teachey DT, Levine B, Milone M, Porter D, June CH. Abstract 4574: Use of CD19-targeted Chimeric Antigen Receptor-modified T (CART19) cells in ALL and CLL produce transient cytokine release syndrome (CRS), macrophage activation syndrome (MAS) and durable responses. Cancer Research. 73: 4574-4574. DOI: 10.1158/1538-7445.Am2013-4574 |
0.35 |
|
| 2012 |
O'Connor RS, Hao X, Shen K, Bashour K, Akimova T, Hancock WW, Kam LC, Milone MC. Substrate rigidity regulates human T cell activation and proliferation. Journal of Immunology (Baltimore, Md. : 1950). 189: 1330-9. PMID 22732590 DOI: 10.4049/jimmunol.1102757 |
0.384 |
|
| 2012 |
Babich A, Li S, O'Connor RS, Milone MC, Freedman BD, Burkhardt JK. F-actin polymerization and retrograde flow drive sustained PLCγ1 signaling during T cell activation. The Journal of Cell Biology. 197: 775-87. PMID 22665519 DOI: 10.1083/Jcb.201201018 |
0.337 |
|
| 2011 |
Biggs MJ, Milone MC, Santos LC, Gondarenko A, Wind SJ. High-resolution imaging of the immunological synapse and T-cell receptor microclustering through microfabricated substrates. Journal of the Royal Society, Interface / the Royal Society. 8: 1462-71. PMID 21490003 DOI: 10.1098/Rsif.2011.0025 |
0.363 |
|
| 2010 |
Tammana S, Huang X, Wong M, Milone MC, Ma L, Levine BL, June CH, Wagner JE, Blazar BR, Zhou X. 4-1BB and CD28 signaling plays a synergistic role in redirecting umbilical cord blood T cells against B-cell malignancies. Human Gene Therapy. 21: 75-86. PMID 19719389 DOI: 10.1089/Hum.2009.122 |
0.451 |
|
| 2010 |
Tsai J, Shen K, Dustin ML, Milone M, Kam LC. Microscale Colocalization of CD3 and CD28 is Required for Activation of Human CD4+ T Cells Biophysical Journal. 98: 406a. DOI: 10.1016/J.Bpj.2009.12.2186 |
0.318 |
|
| 2009 |
Shen K, Milone MC, Dustin ML, Kam LC. Nanoengineering of Immune Cell Function. Materials Research Society Symposia Proceedings. Materials Research Society. 1209. PMID 21562611 DOI: 10.1557/Proc-1209-Yy03-01 |
0.375 |
|
| 2009 |
Milone MC, Fish JD, Carpenito C, Carroll RG, Binder GK, Teachey D, Samanta M, Lakhal M, Gloss B, Danet-Desnoyers G, Campana D, Riley JL, Grupp SA, June CH. Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo. Molecular Therapy : the Journal of the American Society of Gene Therapy. 17: 1453-64. PMID 19384291 DOI: 10.1038/Mt.2009.83 |
0.41 |
|
| 2009 |
Carpenito C, Milone MC, Hassan R, Simonet JC, Lakhal M, Suhoski MM, Varela-Rohena A, Haines KM, Heitjan DF, Albelda SM, Carroll RG, Riley JL, Pastan I, June CH. Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains. Proceedings of the National Academy of Sciences of the United States of America. 106: 3360-5. PMID 19211796 DOI: 10.1073/Pnas.0813101106 |
0.504 |
|
| 2008 |
Varela-Rohena A, Carpenito C, Perez EE, Richardson M, Parry RV, Milone M, Scholler J, Hao X, Mexas A, Carroll RG, June CH, Riley JL. Genetic engineering of T cells for adoptive immunotherapy. Immunologic Research. 42: 166-81. PMID 18841331 DOI: 10.1007/S12026-008-8057-6 |
0.449 |
|
| 2008 |
Huang X, Guo H, Kang J, Choi S, Zhou TC, Tammana S, Lees CJ, Li ZZ, Milone M, Levine BL, Tolar J, June CH, McIvor RS, Wagner JE, Blazar BR, et al. Sleeping beauty transposon-mediated engineering of human primary T cells for therapy of CD19+ lymphoid malignancies Molecular Therapy. 16: 580-589. PMID 18227839 DOI: 10.1038/Sj.Mt.6300404 |
0.413 |
|
| 2007 |
Suhoski MM, Golovina TN, Aqui NA, Tai VC, Varela-Rohena A, Milone MC, Carroll RG, Riley JL, June CH. Engineering artificial antigen-presenting cells to express a diverse array of co-stimulatory molecules. Molecular Therapy : the Journal of the American Society of Gene Therapy. 15: 981-8. PMID 17375070 DOI: 10.1038/Mt.Sj.6300134 |
0.418 |
|
| 2006 |
Zhou X, Huang X, Kang J, Guo H, Choi S, Bassi P, Zhou TC, Milone MC, Levine BL, June CH, McIvor RS, Wagner JE, Blazar BR. Sleeping Beauty (SB) Transposon Mediated Umbilical Cord Blood (UCB) T Cell Therapy for Refractory Acute Lymphoblastic Leukemia (ALL). Blood. 108: 722-722. DOI: 10.1182/Blood.V108.11.722.722 |
0.424 |
|
| 2006 |
Milone MC, Fish J, Carpenito C, Lakal M, Ofori E, Danet-Desnoyers G, Riley JL, Grupp SA, June CH. Chimeric Immunoreceptor (T-Body) Targeting of Acute B-Cell Lymphoblastic Leukemia (B-ALL) through Lentivirus Engineering of Primary Human T Cells. Blood. 108: 3267-3267. DOI: 10.1182/Blood.V108.11.3267.3267 |
0.432 |
|
| Show low-probability matches. |